One of the most differentially methylated genes, PRKACA, has been reported to be differentially expressed in breast cancer tissues of trastuzumab-resistant compared to trastuzumab-sensitive HER2-positive breast cancer patients in two studies included in our systematic review. The gene discussed is ERBB2; the disease is breast carcinoma.